share_log

康寧傑瑞製藥-B：(1)修訂現有持續關連交易的年度上限；及(2)續訂總技術服務協議

ALPHAMAB-B: (1) REVISION OF ANNUAL CAP FOR EXISTING CONTINUING CONNECTED TRANSACTION; AND (2) RENEWAL OF THE MASTER TECHNICAL SERVICE AGREEMENT

香港交易所 ·  Apr 2 08:55
Summary by Moomoo AI
康宁杰瑞制药-B（ALPHAMAB ONCOLOGY）宣布，其全資附屬公司江蘇康寧傑瑞生物製藥有限公司與蘇州康寧傑瑞生物科技有限公司已於2024年4月2日續訂總技術服務協議，有效期至2025年12月31日。該協議允許江蘇康寧傑瑞向蘇州康寧傑瑞提供生產生物製品原液、製劑灌裝及包裝的服務。鑒於預期業務增長，公司建議將截至2024年12月31日止年度的服務費年度上限從人民幣7,860萬元修訂為人民幣10,500萬元。蘇州康寧傑瑞由徐霆博士控制，根據上市規則第14A章，該交易構成關連交易。董事會認為，續訂協議的條款公平合理，符合公司及股東利益。
康宁杰瑞制药-B（ALPHAMAB ONCOLOGY）宣布，其全資附屬公司江蘇康寧傑瑞生物製藥有限公司與蘇州康寧傑瑞生物科技有限公司已於2024年4月2日續訂總技術服務協議，有效期至2025年12月31日。該協議允許江蘇康寧傑瑞向蘇州康寧傑瑞提供生產生物製品原液、製劑灌裝及包裝的服務。鑒於預期業務增長，公司建議將截至2024年12月31日止年度的服務費年度上限從人民幣7,860萬元修訂為人民幣10,500萬元。蘇州康寧傑瑞由徐霆博士控制，根據上市規則第14A章，該交易構成關連交易。董事會認為，續訂協議的條款公平合理，符合公司及股東利益。
ALPHAMAB ONCOLOGY (ALPHAMAB ONCOLOGY) ANNOUNCED THAT ITS WHOLLY OWNED SUBSIDIARIES JIANGSU CONNING GERRY BIOPHARMACEUTICAL CO., LTD. AND SUZHOU CONNING GERRY BIOTECHNOLOGY CO., LTD. HAVE RENEWED A TOTAL TECHNICAL SERVICE AGREEMENT ON APRIL 2, 2024, WHICH WILL BE EFFECTIVE UNTIL DECEMBER 31, 2025. The agreement allows Jiangsu Conning Jerry to provide services for the production of raw materials, preparation filling and packaging of biological products to Suzhou Corning Jerry. In view of the expected business growth, the Company proposes to revise the annual service fee cap for the year ended December 31, 2024 from RMB7,860 million to RMB10,500 million. Suzhou Corning Jerry is controlled by Dr. Xu Ting and constitutes a connected transaction under Chapter 14A of the Listing Rules. The Board considers that the terms of the Renewal Agreement are fair and reasonable and in the best interests of the Company and its shareholders.
ALPHAMAB ONCOLOGY (ALPHAMAB ONCOLOGY) ANNOUNCED THAT ITS WHOLLY OWNED SUBSIDIARIES JIANGSU CONNING GERRY BIOPHARMACEUTICAL CO., LTD. AND SUZHOU CONNING GERRY BIOTECHNOLOGY CO., LTD. HAVE RENEWED A TOTAL TECHNICAL SERVICE AGREEMENT ON APRIL 2, 2024, WHICH WILL BE EFFECTIVE UNTIL DECEMBER 31, 2025. The agreement allows Jiangsu Conning Jerry to provide services for the production of raw materials, preparation filling and packaging of biological products to Suzhou Corning Jerry. In view of the expected business growth, the Company proposes to revise the annual service fee cap for the year ended December 31, 2024 from RMB7,860 million to RMB10,500 million. Suzhou Corning Jerry is controlled by Dr. Xu Ting and constitutes a connected transaction under Chapter 14A of the Listing Rules. The Board considers that the terms of the Renewal Agreement are fair and reasonable and in the best interests of the Company and its shareholders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more